Literature DB >> 29074539

NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem-like Cells.

Carrie D House1, Elizabeth Jordan1, Lidia Hernandez1, Michelle Ozaki1, Jana M James1, Marianne Kim1, Michael J Kruhlak2, Eric Batchelor3, Fathi Elloumi4, Margaret C Cam4, Christina M Annunziata5.   

Abstract

Understanding the mechanisms supporting tumor-initiating cells (TIC) is vital to combat advanced-stage recurrent cancers. Here, we show that in advanced ovarian cancers NFκB signaling via the RelB transcription factor supports TIC populations by directly regulating the cancer stem-like associated enzyme aldehyde dehydrogenase (ALDH). Loss of RelB significantly inhibited spheroid formation, ALDH expression and activity, chemoresistance, and tumorigenesis in subcutaneous and intrabursal mouse xenograft models of human ovarian cancer. RelB also affected expression of the ALDH gene ALDH1A2 Interestingly, classical NFκB signaling through the RelA transcription factor was equally important for tumorigenesis in the intrabursal model, but had no effect on ALDH. In this case, classical signaling via RelA was essential for proliferating cells, whereas the alternative signaling pathway was not. Our results show how NFκB sustains diverse cancer phenotypes via distinct classical and alternative signaling pathways, with implications for improved understanding of disease recurrence and therapeutic response. Cancer Res; 77(24); 6927-40. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29074539      PMCID: PMC5732863          DOI: 10.1158/0008-5472.CAN-17-0366

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Identification of CD44 as a downstream target of noncanonical NF-κB pathway activated by human T-cell leukemia virus type 1-encoded Tax protein.

Authors:  Jing Zhang; Osamu Yamada; Shinya Kida; Yoshihisa Matsushita; Shoji Yamaoka; Haorile Chagan-Yasutan; Toshio Hattori
Journal:  Virology       Date:  2011-03-15       Impact factor: 3.616

Review 2.  Crosstalk in NF-κB signaling pathways.

Authors:  Andrea Oeckinghaus; Matthew S Hayden; Sankar Ghosh
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

3.  Cancer: Clonal cooperation.

Authors:  Kornelia Polyak; Andriy Marusyk
Journal:  Nature       Date:  2014-04-03       Impact factor: 49.962

4.  Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo.

Authors:  Kashmira Kulkarni-Datar; Sandra Orsulic; Rosemary Foster; Bo R Rueda
Journal:  Cancer Lett       Date:  2013-06-18       Impact factor: 8.679

5.  Epigenetic targeting of ovarian cancer stem cells.

Authors:  Yinu Wang; Horacio Cardenas; Fang Fang; Salvatore Condello; Pietro Taverna; Matthew Segar; Yunlong Liu; Kenneth P Nephew; Daniela Matei
Journal:  Cancer Res       Date:  2014-07-17       Impact factor: 12.701

6.  Prognostic value of cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysis.

Authors:  Shuyan Liu; Chengfei Liu; Xiaoyun Min; Yuanyuan Ji; Na Wang; Dan Liu; Jiangyi Cai; Ke Li
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

7.  Screening of potentially crucial genes and regulatory factors involved in epithelial ovarian cancer using microarray analysis.

Authors:  Can Shi; Zhenyu Zhang
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

8.  Treatment for recurrent ovarian cancer-at first relapse.

Authors:  Kimio Ushijima
Journal:  J Oncol       Date:  2009-12-24       Impact factor: 4.375

9.  Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer.

Authors:  Ritu Arora; Clayton Yates; Bernard D Gary; Steven McClellan; Ming Tan; Yaguang Xi; Eddie Reed; Gary A Piazza; Laurie B Owen; Windy Dean-Colomb
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

10.  Prognostic values of aldehyde dehydrogenase 1 isoenzymes in ovarian cancer.

Authors:  Yu-Mei Ma; Shan Zhao
Journal:  Onco Targets Ther       Date:  2016-04-04       Impact factor: 4.147

View more
  40 in total

1.  MTSS1 suppresses mammary tumor-initiating cells by enhancing RBCK1-mediated p65 ubiquitination.

Authors:  Min Cong; Yuan Wang; Yang Yang; Cheng Lian; Xueqian Zhuang; Xiaoxun Li; Peiyuan Zhang; Yingjie Liu; Jun Tang; Qifeng Yang; Xue Zhang; Hua Xiong; Ronggui Hu; Guohong Hu
Journal:  Nat Cancer       Date:  2020-01-20

2.  Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview.

Authors:  Orlandric Miree; Sanjeev Kumar Srivastava; Santanu Dasgupta; Seema Singh; Rodney Rocconi; Ajay Pratap Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

4.  Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK.

Authors:  Sandeep Rana; Smit Kour; Yogesh A Sonawane; Caroline M Robb; Jacob I Contreras; Smitha Kizhake; Muhammad Zahid; Adam R Karpf; Amarnath Natarajan
Journal:  Chem Biol Drug Des       Date:  2020-04-22       Impact factor: 2.817

Review 5.  The importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT.

Authors:  Eui Jung Moon; Kristoffer Petersson; Monica M Olcina
Journal:  Int J Radiat Biol       Date:  2021-11-02       Impact factor: 2.694

Review 6.  Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets.

Authors:  Takahiko Murayama; Noriko Gotoh
Journal:  Cancer Drug Resist       Date:  2019-09-19

7.  IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.

Authors:  Carrie D House; Valentina Grajales; Michelle Ozaki; Elizabeth Jordan; Helmae Wubneh; Danielle C Kimble; Jana M James; Marianne K Kim; Christina M Annunziata
Journal:  BMC Cancer       Date:  2018-05-25       Impact factor: 4.430

8.  STX2 promotes colorectal cancer metastasis through a positive feedback loop that activates the NF-κB pathway.

Authors:  Yongxia Wang; Honghai Xu; Hongli Jiao; Shuyang Wang; Zhiyuan Xiao; Yali Zhao; Jiaxin Bi; Wenting Wei; Shanshan Liu; Junfeng Qiu; Tingting Li; Li Liang; Yaping Ye; Wenting Liao; Yanqing Ding
Journal:  Cell Death Dis       Date:  2018-05-31       Impact factor: 8.469

9.  Chemopreventive activity of celastrol in drug-resistant human colon carcinoma cell cultures.

Authors:  Helena Moreira; Anna Szyjka; Kazimierz Gąsiorowski
Journal:  Oncotarget       Date:  2018-04-20

10.  Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer.

Authors:  Yu-Xin Jiang; Michelle Kwan-Yee Siu; Jing-Jing Wang; Xue-Tang Mo; Thomas Ho-Yin Leung; David Wai Chan; Annie Nga-Yin Cheung; Hextan Yuen-Sheung Ngan; Karen Kar-Loen Chan
Journal:  Br J Cancer       Date:  2020-05-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.